Systemo-pulmonary shunting and acute chest syndrome in a patient with SC sickle-cell disease

2020 ◽  
Vol 77 ◽  
pp. 21-23
Author(s):  
F. Schlemmer ◽  
J. Gellen-Dautremer ◽  
M.F. Carette ◽  
N. de Prost ◽  
S. Spagnolo ◽  
...  
Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3673-3673
Author(s):  
Payal C. Desai ◽  
Nicole Kendel ◽  
Melanie Heinlein ◽  
Ying Huang ◽  
Eric H. Kraut ◽  
...  

Abstract Introduction: During an episode of vaso-occlusive crisis, some patients with sickle cell disease may develop a transient hypoxemia. While frequently attributed to acute chest syndrome or pulmonary embolism, clinically a portion of patients develop hypoxemia without a clear etiology. On echocardiography, some patients were noted to have Patent Foramen Ovale (PFO) and others were noted to have intrapulmonary shunting. We sought to further characterize this clinical finding in sickle cell patients. Methods: We conducted a single institution retrospective chart review from 2008 through 2015 to evaluate the incidence of pulmonary shunting and PFOs in patients with SCD, as demonstrated on an echocardiography. We further characterize each of these episodes with clinical and laboratory findings at the time of the event. The presence of absence of shunting and type of shunting was further verified by a single cardiologist reviewing all episodes. Kruskal-Wallis test or Fisher's exact test was used to compare characteristics between patients with intracardiac or intrapulmonary shunting. Results: A total of 36 (18 female (F), 18 male (M)) of the 352 (10%) patients seen at the Ohio State Comprehensive Sickle Cell Center were noted to have shunting on their echocardiogram reported over the 7 year time period. Independent review by cardiology confirmed the presence of a shunt in 32 patients (9%, 95% CI: 6-13%) (15F, 17M). The median age at the time of reporting was 29 (range: 18-51 yrs). Shunting was observed in patients of all genotypes (94% SS/SB0; 6% SC/SBeta+). Fourteen (6 F, 8 M) of the thirty-two (44%, 95% CI: 26-62%) patients under study were noted to have cardiac shunting and eighteen (9 F, 9 M) (56%, 95% CI: 38-74%) were noted to have pulmonary shunting. In the patients with cardiac shunting, all 14/14 were confirmed to have a PFO by independent cardiac review. At the time of echo, 27/32 (87%) were hospitalized and 19/32 (59%) had clinical hypoxia on the day of the echocardiography. Patients with cardiac shunting tended to have higher proportion of hypoxia compared with patients with pulmonary shunting (71% vs. 50%). 19/32 (59%) had concurrent CT angiography and 1/32 (5%) patients was confirmed to have a pulmonary embolism. This patient demonstrated a concurrent PFO. 9 (28%) had a concurrent diagnosis of acute chest syndrome (4 with cardiac shunting and 5 with pulmonary shunting). The median value of TR jet velocity at baseline was 2.64 (range: 2.0-4.0) (n=18) and the median TR jet velocity at the time of event was 2.67 m/s (range: 2.0-3.8 m/s) (n=27). In the cardiac shunting group, the TR jet velocity was 2.85 m/s (range: 2.0 -3.27m/s) and in the pulmonary shunting group, the TR jet velocity was 2.6 m/s (range: 2.2-3.8 m/s). Conclusion: Patients with SCD presenting with increasing hypoxia may have intracardiac or intrapulmonary shunting. A patent foramen ovale that opens during vaso-ossclusive crisis may cause transient hypoxemia. This opening is thought to be due to increasing pulmonary pressures. While the long term implications of this finding are currently being studied, intracardiac shunting should be considered in the differential of patients with SCD presenting with increasing hypoxia of unclear etiology. Disclosures No relevant conflicts of interest to declare.


Author(s):  
Soi Avgeridou ◽  
Ilija Djordjevic ◽  
Anton Sabashnikov ◽  
Kaveh Eghbalzadeh ◽  
Laura Suhr ◽  
...  

AbstractExtracorporeal membrane oxygenation (ECMO) plays an important role as a life-saving tool for patients with therapy-refractory cardio-respiratory failure. Especially, for rare and infrequent indications, scientific data is scarce. The conducted paper focuses primarily on our institutional experience with a 19-year-old patient suffering an acute chest syndrome, a pathognomonic pulmonary condition presented by patients with sickle cell disease. After implementation of awake ECMO therapy, the patient was successfully weaned off support and discharged home 22 days after initiation of the extracorporeal circulation. In addition to limited data and current literature, further and larger data sets are necessary to determine the outcome after ECMO therapy for this rare indication.


Toxins ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 157
Author(s):  
Joyce Gonzales ◽  
Trinad Chakraborty ◽  
Maritza Romero ◽  
Mobarak Abu Mraheil ◽  
Abdullah Kutlar ◽  
...  

Sickle cell disease (SCD) is one of the most common autosomal recessive disorders in the world. Due to functional asplenia, a dysfunctional antibody response, antibiotic drug resistance and poor response to immunization, SCD patients have impaired immunity. A leading cause of hospitalization and death in SCD patients is the acute chest syndrome (ACS). This complication is especially manifested upon infection of SCD patients with Streptococcus pneumoniae (Spn)—a facultative anaerobic Gram-positive bacterium that causes lower respiratory tract infections. Spn has developed increased rates of antibiotics resistance and is particularly virulent in SCD patients. The primary defense against Spn is the generation of reactive oxygen species (ROS) during the oxidative burst of neutrophils and macrophages. Paradoxically, Spn itself produces high levels of the ROS hydrogen peroxide (H2O2) as a virulence strategy. Apart from H2O2, Spn also secretes another virulence factor, i.e., the pore-forming exotoxin pneumolysin (PLY), a potent mediator of lung injury in patients with pneumonia in general and particularly in those with SCD. PLY is released early on in infection either by autolysis or bacterial lysis following the treatment with antibiotics and has a broad range of biological activities. This review will discuss recent findings on the role of pneumococci in ACS pathogenesis and on strategies to counteract the devastating effects of its virulence factors on the lungs in SCD patients.


2021 ◽  
pp. 1-5
Author(s):  
Justin E. Juskewitch ◽  
Craig D. Tauscher ◽  
Sheila K. Moldenhauer ◽  
Jennifer E. Schieber ◽  
Eapen K. Jacob ◽  
...  

Introduction: Patients with sickle cell disease (SCD) have repeated episodes of red blood cell (RBC) sickling and microvascular occlusion that manifest as pain crises, acute chest syndrome, and chronic hemolysis. These clinical sequelae usually increase during pregnancy. Given the racial distribution of SCD, patients with SCD are also more likely to have rarer RBC antigen genotypes than RBC donor populations. We present the management and clinical outcome of a 21-year-old pregnant woman with SCD and an RHD*39 (RhD[S103P], G-negative) variant. Case Presentation: Ms. S is B positive with a reported history of anti-D, anti-C, and anti-E alloantibodies (anti-G testing unknown). Genetic testing revealed both an RHD*39 and homozygous partial RHCE*ceVS.02 genotype. Absorption/elution testing confirmed the presence of anti-G, anti-C, and anti-E alloantibodies but could not definitively determine the presence/absence of an anti-D alloantibody. Ms. S desired to undergo elective pregnancy termination and the need for postprocedural RhD immunoglobulin (RhIG) was posed. Given that only the G antigen site is changed in an RHD*39 genotype and the potential risk of RhIG triggering a hyperhemolytic episode in an SCD patient, RhIG was not administered. There were no procedural complications. Follow-up testing at 10 weeks showed no increase in RBC alloantibody strength. Discussion/Conclusion: Ms. S represents a rare RHD*39 and partial RHCE*ceVS.02 genotype which did not further alloimmunize in the absence of RhIG administration. Her case also highlights the importance of routine anti-G alloantibody testing in women of childbearing age with apparent anti-D and anti-C alloantibodies.


1995 ◽  
Vol 62 (2) ◽  
pp. 201-205 ◽  
Author(s):  
H. A. Srair ◽  
J. A. Owa ◽  
H. A. Aman ◽  
M. A. Madan

2008 ◽  
Vol 6 (3) ◽  
pp. 220-223 ◽  
Author(s):  
B. Diarra ◽  
J. Roudié ◽  
A. Coulibaly ◽  
F. Ehua Somian ◽  
J.-B. Kanga-Miessan ◽  
...  

2002 ◽  
Vol 2 ◽  
pp. 1706-1728 ◽  
Author(s):  
Martin H. Steinberg

High fetal hemoglobin (HbF) levels inhibit the polymerization of sickle hemoglobin (HbS) and reduce the complications of sickle cell disease. Pharmacologic agents that can reverse the switch from γ- to β-chain synthesis — γ-globin chains characterize HbF, and sickle β-globin chains are present in HbS — or selectively increase the proportion of adult erythroid precursors that maintain the ability to produce HbF are therapeutically useful. Hydroxyurea promotes HbF production by perturbing the maturation of erythroid precursors. This treatment increases the total hemoglobin concentration, reduces the vaso-occlusive complications of pain and acute chest syndrome, and attenuates mortality in adults. It is a promising beginning for pharmacologic therapy of sickle cell disease. Still, its effects are inconsistent, trials in infants and children are ongoing, and its ultimate value — and peril — when started early in life are still unknown.


2020 ◽  
Vol 11 ◽  
Author(s):  
Vanessa Araujo Gomes Santaterra ◽  
Maiara Marx Luz Fiusa ◽  
Bidossessi Wilfried Hounkpe ◽  
Francine Chenou ◽  
Wouitchekpo Vincent Tonasse ◽  
...  

Free extracellular heme has been shown to activate several compartments of innate immunity, acting as a danger-associated molecular pattern (DAMP) in hemolytic diseases. Although localized endothelial barrier (EB) disruption is an important part of inflammation that allows circulating leukocytes to reach inflamed tissues, non-localized/deregulated disruption of the EB can lead to widespread microvascular hyperpermeability and secondary tissue damage. In mouse models of sickle cell disease (SCD), EB disruption has been associated with the development of a form of acute lung injury that closely resembles acute chest syndrome (ACS), and that can be elicited by acute heme infusion. Here we explored the effect of heme on EB integrity using human endothelial cell monolayers, in experimental conditions that include elements that more closely resemble in vivo conditions. EB integrity was assessed by electric cell-substrate impedance sensing in the presence of varying concentrations of heme and sera from SCD patients or healthy volunteers. Heme caused a dose-dependent decrease of the electrical resistance of cell monolayers, consistent with EB disruption, which was confirmed by staining of junction protein VE-cadherin. In addition, sera from SCD patients, but not from healthy volunteers, were also capable to induce EB disruption. Interestingly, these effects were not associated with total heme levels in serum. However, when heme was added to sera from SCD patients, but not from healthy volunteers, EB disruption could be elicited, and this effect was associated with hemopexin serum levels. Together our in vitro studies provide additional support to the concept of heme as a DAMP in hemolytic conditions.


Sign in / Sign up

Export Citation Format

Share Document